Literature DB >> 2339482

Prostatic acid phosphatase in the serially transplantable human prostatic tumor lines PC-82 and PC-EW.

Z Csapo1, K Brand, K M Schrott, B Schwindl.   

Abstract

The correlation between tumor volume of untreated tumor-bearing nude mice and serum concentration of prostatic acid phosphatase (PAP/RIA) was studied in the hormone-dependent serially transplantable human prostatic tumor models PC-82 and PC-EW. The normal serum level of PAP in control male nude mice without tumor was found to be 0.9 +/- 0.3 ng/ml. Elevated PAP serum concentrations were never found in animals without tumor (a highly specific diagnostic technique). A close correlation was observed between the concentration of PAP in the serum (range 0.3 to 154 ng/ml) and the tumor volume (range 10.0 to 6,530 mm3) of 104 untreated mice bearing a PC-82 or PC-EW human prostatic tumor. This correlation was comparable in both tumor lines (p less than 0.001). The positive effect of endocrine manipulation which resulted in tumor diameter decrease or growth arrest with regressive histological patterns, showed the normal PAP serum level, too. After successful treatment PAP was found to be normal, independent from the residual tumor mass. By contrast, in the event of only retarded tumor growth, the PAP level still correlated with the tumor burden.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2339482     DOI: 10.1007/bf00302475

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  12 in total

1.  AN " ACID " PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND.

Authors:  A B Gutman; E B Gutman
Journal:  J Clin Invest       Date:  1938-07       Impact factor: 14.808

2.  Elevated prostatic acid phosphatase: a prognostic factor for stage C adenocarcinoma of the prostate.

Authors:  R J Babaian; R P Orlando
Journal:  J Urol       Date:  1986-11       Impact factor: 7.450

3.  The radioimmunochemical measurement of prostatic acid phosphatase: current state of the art.

Authors:  J F Cooper
Journal:  Urol Clin North Am       Date:  1980-10       Impact factor: 2.241

4.  New screening and diagnostic tests for prostate cancer and immunologic assessment.

Authors:  W J Catalona; M Menon
Journal:  Urology       Date:  1981-03       Impact factor: 2.649

5.  [Diagnosis and follow-up of prostatic cancer using an enzyme immunoassay for prostate-specific acid phosphatase].

Authors:  H W Bauer; J Schüller; E Schmiedt; F Dati
Journal:  Helv Chir Acta       Date:  1981-08

6.  Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC 82).

Authors:  W Hoehn; F H Schroeder; J F Reimann; A C Joebsis; P Hermanek
Journal:  Prostate       Date:  1980       Impact factor: 4.104

7.  Current experience with radioimmunoassay techniques for prostatic acid phosphatase.

Authors:  J F Cooper; W D Finkle
Journal:  Prostate       Date:  1980       Impact factor: 4.104

8.  Prostatic adenocarcinoma PC EW, a new human tumor line transplantable in nude mice.

Authors:  W Hoehn; M Wagner; J F Riemann; P Hermanek; E Williams; R Walther; R Schrueffer
Journal:  Prostate       Date:  1984       Impact factor: 4.104

9.  Effect of hormone treatment on prostatic acid phosphatase in a serially transplantable human prostatic adenocarcinoma (PC-82).

Authors:  G J Van Steenbrugge; M A Blankenstein; J Bolt-de Vries; J C Romijn; F H Schröder; P Vihko
Journal:  J Urol       Date:  1983-03       Impact factor: 7.450

10.  Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase.

Authors:  A G Foti; J F Cooper; H Herschman; R R Malvaez
Journal:  N Engl J Med       Date:  1977-12-22       Impact factor: 91.245

View more
  1 in total

Review 1.  Serially heterotransplanted human prostate tumours as an experimental model.

Authors:  Lluis-A Lopez-Barcons
Journal:  J Cell Mol Med       Date:  2009-10-29       Impact factor: 5.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.